Localized angiofollicular hyperplasia, otherwise known as Castleman's disease, is described in the lymph nodes of 2 mice of different strains, one inoculated with polyoma virus at birth and the other given urethane within 24 hr of birth. A plasma cell component in the lesion, suggestive of bone marrow stem cell involvement, was present in the mouse treated with polyoma virus but absent in the mouse given intraperitoneal urethane. Dysregulated interleukin 6 has recently been reported to produce the systemic variety of angiofollicular hyperplasia in mice, but the role of this cytokine in the localized variety described in this report is not known. This lesion appears to be rare in mice, but when present it could easily be missed or overlooked because the typical layering of follicle cells and the relatively large germinal centers seen in humans do not appear prominent in mice. Although there is, obviously, no proof of a causal relationship between the lesion and polyoma virus or urethane, it is suggested that this lesion be searched for in order to estimate its frequency and possible etiologic associations.
1. Al-Jabi M and McCaughey WTE (1981). Multicentric angiofollicular lymph node hyperplasia. Cancer Med. Assoc. J124: 1023–1025.
2.
2. Al-Jabi M, Tolnai G, and McCaughey WTE (1980). Angiofollicular lymphoid hyperplasia in an angiolipomatous man. Arch. Pathol. Lab. Med104: 313–315.
3.
3. Abell MR (1957). Lymph nodal hamartoma versus thymic choristoma of pulmonary hilum. AMA Arch. Pathol64: 584–588.
4.
4. Bartoli E, Mamarelli G, Soggia G, and Tanda F (1980). Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am. J. Clin. Pathol73: 423–426.
5.
5. Brandt SJ, Bodine DM, Dunbar CE, and Nienhuis AW (1990). Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest86: 592–599.
6.
6. Brandt SJ, Bodine DM, Dunbar CE, and Nienhuis AW (1990). Retroviral-mediated transfer of interleukin-6 into hematopoeitic cells of mice results in a syndrome resembling Castleman's disease. Curr. Top. Micro. Immunol166: 38–41.
8. Chen KTK (1984). Multicentric Castleman's disease and Kaposi's sarcoma. Am. J. Surg. Pathol8: 287–290.
9.
9. Chiu CP, Moulds C, Coffman RL, Rennick D, and Lee, F (1988). Multiple biological activities are expressed by bone marrow stromal cells. Proc. Natl. Acad. Sci. USA85: 7099–7103.
10.
10. Dawe CJ, Law LW, and Dunn TB (1959). Studies of parotid-tumor agent in cultures of leukemic tissues of mice. J. Natl. Cancer Inst23: 717–797.
11.
11. Fayemi AO and Toker C (1975). Nodal angiomatosis. Arch. Pathol99: 170–172.
12.
12. Flendrig JA and Schillings PHM (1970). Benign giant lymphoma: Clinico-pathologic correlation study. In: The Year Book of Cancer, RL Clark and RS Cumley (eds). Chicago Year Book Medical Publishers, Chicago, Illinois, pp. 296–302.
13.
13. Frizzera G (1985). Castleman's disease: More questions than answers. Hum. Pathol16: 202–205.
14.
14. Frizzera G (1988). Castleman's disease and related disorders. Sem. Diag. Pathol5: 346–364.
15.
15. Frizzera G and Banks PM (1982). Splenic involvement in “so-called” multicentric giant lymph node hyperplasia (MGLH). Lab. Invest46: 26 (abstract).
16.
16. Frizzera G, Peterson BA, and Bayrd ED (1983). A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am. J. Surg. Pathol7: 211–231.
17.
17. Frizzera G, Peterson BA, Bayrd ED, and Goldman A (1985). A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Clinical findings and clinico-pathologic correlations in 15 patients. J. Clin. Oncol3: 1202–1216.
18.
18. Grossman RM, Krueger D, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kuper TS, Sehgal PB, and Gottlieb AB (1989). Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA86: 6367–6371.
19.
19. Hanson CA, Frizzera G, Patton DF, Peterson BA, McClain KL, Gajl-Peczalska KJ, and Kersey JH (1988). Clonal rearrangement for immunoglobulin and T cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. Am. J. Pathol131: 84–91.
20.
20. Harrison EG Jr and Bernatz PE (1963). Angiofollicular mediastinal lymph node hyperplasia resembling thymoma. Arch. Pathol75: 284–292.
21.
21. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaixnes CN, and Van Snick J (1988). Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arthritis Rheum31: 784–788.
22.
22. Keller AR, Hochholzer L, and Castleman B (1972). Hyaline vascular and plasma cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer29: 670–673.
23.
23. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, and Battaille R (1989). Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood73: 517–526.
24.
24. Kohase M, Henriken-de Stefano D, May LT, Vikek J, and Sehgal PB (1986). Induction of β2 interferon by tumor necrosis factor: A homeostatic mechanism in the control of cell proliferation. Cell45: 659–666.
25.
25. Miki S, Iwano U, Miki M, Yamamoto B, Pang B, Yokokawa K, Sonoda T, Hirano T, and Kishimoto T (1989). Interleukin-6 (IL-6) functions as an in-vitro autocrine growth factor in renal cell carcinomas. FEBS Lett250: 607–610.
26.
26. Mushinski JF (1988). C-myc oncogene activation and chromosomal translocation in BALB/c plasmacytomas. In: Cellular Oncogene Activation, G Klein (ed). Marcel Dekker, New York, pp. 181–192.
27.
27. Nakajima KO, Martinez-Maza O, Hirano T, and Breen PG (1989). Induction of IL-6 (B cell stimulatory factor-2(1FN-β2), production by HIV. J. Immunol142: 531–536.
28.
28. Sehgal PB, Helfgott DC, Santhanam U, Tatter SB, Clarick RH, Ghrayeb J, and May LT (1988). Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the B2-inter-feron/hepatocyte-stimulating factor; interleukin 6 gene in virus-infected human fibroblasts. J. Exp. Med167: 1951–1956.
29.
29. Walther Z, May LT, and Sehgal PB (1988). Transcriptional factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J. Immunol140: 974–977.
30.
30. Weisenburger DD (1979). Membranous nephropathy: Its association with multicentric angiofollicular lymph node hyperplasia. Arch. Pathol. Lab. Med103: 591–594.
31.
31. Weisenburger DD, Nathwani BN, Winberg CD, and Rappaport H (1985). Multicentric angiofollicular lymph node hyperplasia. A clinico-pathologic study of 16 cases. Hum. Pathol16: 162–165.
32.
32. Williams AO (1992). HIV and malignant diseases in Africa. In: AIDS—An African Perspective, AO Williams (ed). CRC Press, Boca Raton, Florida, pp. 282–289.
33.
33. Yee CA, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, and Minden MD (1989). A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood74: 798–804.
34.
34. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, and Komori T (1989). Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood74: 1360–1367.
